A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 38/20 (2006.01) A61K 31/7048 (2006.01) A61K 39/395 (2006.01) A61P 33/00 (2006.01)
Patent
CA 2500723
This invention relates to a method for treating a patient having a fungal infection. The invention comprises administering to the patient a therapeutically effective amount of a polyene antifungal (e.g., amphotericin B) in association with a therapeutically effective amount of a interleukin-2 inhibitor (e.g., chimeric or humanized monoclonal antibody that binds to the p55 subunit of the human interleukin-2 receptor and inhibits binding of interleukin-2 to an interleukin-2 receptor).
Cette invention a trait à une méthode de traitement d'un patient atteint d'infection fongique. La méthode consiste à administrer à ce patient une quantité efficace du point de vue thérapeutique d'un antifongique polyène (par exemple, de l'amphotéricine B) associé à une quantité efficace du point de vue thérapeutique d'un inhibiteur de l'interleukine 2 (par exemple un anticorps monoclonal chimérique ou humanisé, se fixant à la sous-unité p55 du récepteur de l'interleukine 2 et inhibant la fixation de l'interleukine 2 à un récepteur de cette même interleukine 2).
Chapman Stanley Willetts
Cleary John D.
Gordon Robert D.
Borden Ladner Gervais Llp
F. Hoffmann-La Roche Ag
The University Of Mississippi
The University Of Mississippi Medical Center
LandOfFree
Use of il-2 receptor antibodies to prevent toxicity... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of il-2 receptor antibodies to prevent toxicity..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of il-2 receptor antibodies to prevent toxicity... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2017213